Analyst Ratings for Karuna Therapeutics
As of November 20, 2023, a total of 8 analysts have shared their views on the stock of Karuna Therapeutics (NASDAQ: KRTX). Let’s take a closer look at their ratings:
– Bullish: 4 analysts have expressed a bullish sentiment towards Karuna Therapeutics.
– Somewhat Bullish: Another 4 analysts have shown a somewhat bullish outlook on the stock.
– Indifferent: None of the analysts have expressed an indifferent stance.
– Somewhat Bearish: There are no analysts with a somewhat bearish view.
– Bearish: Similarly, no analysts have a bearish opinion on Karuna Therapeutics.
Considering these ratings, it is evident that the majority of analysts have a positive outlook on the company’s stock.
The average price target set by these analysts is $275.5, which indicates potential upside. Currently, Karuna Therapeutics is trading at $179.73. It is important to note that the average price target has decreased by 1.69% compared to the previous average of $280.25.
Analysts arrive at their ratings by making predictions about a company’s future earnings and assessing the associated risks. They conduct thorough research, attend company events, analyze financial statements, and engage with insiders to gather insights. Some analysts even provide forecasts for various metrics like growth estimates, earnings, and revenue to offer additional guidance to investors.
Based on the ratings provided by these analysts, Karuna Therapeutics has a consensus rating of Strong Buy. This rating is derived from 11 buy ratings, 0 hold ratings, and 0 sell ratings.
Investors who rely on analyst ratings should remember that these ratings are based on predictions and should be considered in conjunction with other factors when making investment decisions.
For more detailed information on stock ratings and to follow the top analysts on Wall Street, investors can visit the Expert Center, which provides a list of the top 100 Wall Street analysts. This allows investors to choose and follow the analysts of their preference.
To stay updated on the latest analyst ratings for Karuna Therapeutics, investors can visit various financial websites that track analyst ratings and stock expectations, such as Benzinga, Yahoo Finance, and others.
Karuna Therapeutics, Inc.
KRTX
Buy
Updated on: 02/12/2023
Financial Health
Healthy
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Neutral
KRTX Stock Analysis: Declining Earnings and Revenue Growth Raise Concerns
On November 20, 2023, KRTX stock opened at $180.37, slightly higher than the previous day’s closing price of $179.77. Throughout the day, the stock experienced a trading range between $178.97 and $182.27. The volume for the day was 2,384 shares, which is significantly lower than the average volume of 245,266 shares over the past three months. The market capitalization of KRTX stands at $6.8 billion.
KRTX has experienced a decline in earnings growth over the past year, with a decrease of 77.03%. Moreover, the earnings growth for this year stands at -33.78%, indicating a continued downward trend. Looking ahead, the projected earnings growth for the next five years is expected to be -72.72%.
Similarly, KRTX has witnessed a decline in revenue growth, with a decrease of 71.22% in the last year. These figures raise concerns about the company’s ability to generate consistent revenue and profitability.
The price-to-earnings (P/E) ratio for KRTX is listed as NM, indicating that the company is currently not generating positive earnings. This could be a result of the significant losses reported in the previous year. The price-to-sales ratio is quite high at 584.29, suggesting that the stock may be overvalued based on its sales performance. The price-to-book ratio of 5.15 indicates that the stock is trading above its book value.
KRTX operates in the health technology sector, specifically in the pharmaceuticals: major industry. The company’s corporate headquarters are located in Boston, Massachusetts. However, no executives are currently listed.
Looking ahead, investors should closely monitor KRTX’s next reporting date, which is set for February 22, 2024. This will provide further insights into the company’s financial performance and future prospects. The forecasted earnings per share (EPS) for this quarter is -$3.22, indicating a potential loss.
It is important to note that KRTX’s financial indicators and stock performance on November 20, 2023, suggest a challenging situation for the company. Investors should conduct further research and analysis before making any investment decisions related to KRTX stock.
Karuna Therapeutics Inc (KRTX) Stock Shows Promising Performance and Potential for Growth
On November 20, 2023, Karuna Therapeutics Inc (KRTX) stock showed promising performance based on the information provided by CNN Money. The 18 analysts offering 12-month price forecasts for KRTX have a median target of $269.00, with a high estimate of $320.00 and a low estimate of $197.00. This indicates a potential increase of 48.87% from the last recorded price of $180.70.
The consensus among 19 polled investment analysts is to buy stock in Karuna Therapeutics Inc, a rating that has remained steady since November. This buy rating suggests that the analysts believe in the future growth and potential of the company.
Karuna Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for neuropsychiatric disorders. Their research and development efforts are centered around targeting the muscarinic cholinergic receptors in the brain, aiming to address the underlying causes of various psychiatric and neurological conditions.
Investors may see this as an opportunity to invest in a company with potential for significant growth.
Karuna Therapeutics Inc is scheduled to report its current quarter earnings on February 22. This information will provide further insight into the company’s financial performance and may impact the stock’s future trajectory. Investors should stay updated on the company’s news and announcements to make informed investment decisions.
Discussion about this post